We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ocuphire Pharma Inc | NASDAQ:OCUP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 2.98% | 1.73 | 1.72 | 1.73 | 1.76 | 1.70 | 1.70 | 70,539 | 20:32:47 |
Delaware
|
11-3516358
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number.)
|
37000 Grand River Avenue, Suite 120
Farmington Hills, MI
|
48335
|
|
(Address of principal executive offices)
|
(Zip code)
|
Ocuphire Pharma, Inc. 2020 Equity Incentive Plan
|
(Full title of the plan)
|
Dr. George Magrath
Chief Executive Officer
Ocuphire Pharma, Inc.
37000 Grand River Avenue, Suite 120
Farmington Hills, MI 48335
(248) 957-9024
|
(Name, address, and telephone number, including area code, of agent for service)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
Emerging growth company ☐
|
Item 3. |
Incorporation of Documents By Reference.
|
(a) |
the Registrant’s Annual Report on Form 10-K filed on March 30, 2023;
|
(b) |
the Registrant’s Quarterly Reports on Form 10-Q filed on May 15, 2023, August 11, 2023 and November 13, 2023;
|
(c) |
the Registrant’s Current Reports on Form 8-K filed on January 25, 2023, April 21, 2023, June 2, 2023, June 9, 2023, June 14, 2023, August 11, 2023, September 27, 2023, November 1, 2023, November 2, 2023, November 27, 2023 and December 6, 2023; and
|
(d) |
the description of the Company’s Common Stock contained in the Company’s Form 8-A (File No. 001-34079), as filed with the Commission pursuant to Sections 12(b) and 12(g) of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), on May
23, 2008.
|
Item 8. |
Exhibits.
|
Exhibit
Number
|
Description
|
|
Amended and Restated Certificate of Incorporation (incorporated by reference to Appendix G to the Company’s Definitive Proxy Statement on Schedule 14A, filed on April 29, 2005)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on May 5, 2017)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on August 30, 2018)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on April 12, 2019).
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on November 6, 2020)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed on November 6, 2020)
|
||
Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K, filed on November 6, 2020)
|
||
First Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on June 10, 2022)
|
||
Second Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on June 17, 2022)
|
||
Third Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on June 2, 2023)
|
||
Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Annex D to the Company’s Registration Statement on Form S-4, filed on September 30, 2020)
|
||
Opinion of Honigman LLP
|
||
Consent of Ernst & Young LLP
|
||
Consent of Honigman LLP (included in Exhibit 5.1)
|
||
Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)
|
||
Filing Fee Table
|
OCUPHIRE PHARMA, INC.
|
|||
By:
|
/s/ Dr. George Magrath
|
||
Name:
|
Dr. George Magrath
|
||
Title:
|
Chief Executive Officer
|
SIGNATURE
|
TITLE
|
DATE
|
||
/s/ Dr. George Magrath
|
||||
Dr. George Magrath
|
Chief Executive Officer & Director
(Principal Executive Officer)
|
January 11, 2024
|
||
/s/ Amy Rabourn
|
||||
Amy Rabourn
|
Senior Vice President of Finance
(Principal Financial and Accounting Officer)
|
January 11, 2024
|
||
/s/ Sean Ainsworth
|
||||
Sean Ainsworth
|
Director
|
January 11, 2024
|
||
/s/ James S. Manuso
|
||||
James S. Manuso
|
Director
|
January 11, 2024
|
||
/s/ Cam Gallagher
|
||||
Cam Gallagher
|
Director
|
January 11, 2024
|
||
/s/ Jay Pepose
|
||||
Jay Pepose
|
Director
|
January 11, 2024
|
||
/s/ Richard Rodgers
|
||||
Richard Rodgers
|
Director
|
January 11, 2024
|
||
/s/ Susan K. Benton
|
||||
Susan K. Benton
|
Director
|
January 11, 2024
|
269.337.7700
|
Re: |
Registration Statement on Form S-8
|
Very truly yours,
|
|
/s/ Honigman LLP
|
|
HONIGMAN LLP
|
Honigman LLP • 650 Trade Centre Way • Suite 200 • Kalamazoo, Michigan 49002-0402
|
Security
Type
|
Security Class Title
|
Fee
Calculation
Rule
|
Amount
Registered
(1)
|
Proposed
Maximum
Offering Price
Per Unit
|
Maximum
Aggregate Offering Price (2)
|
Fee Rate
|
Amount of
Registration
Fee
|
|||||||||
Fees to be Paid
|
||||||||||||||||
Equity
|
Common Stock, par value $0.0001 per share, to be issued under the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan
|
Other (2)
|
1,198,875 (3)
|
$3.055 (2)
|
$0.0001476
|
|||||||||||
Total Offering Amounts
|
$3,662,563.13
|
$540.59
|
||||||||||||||
Total Fees Previously Paid
|
$0.00
|
|||||||||||||||
Total Fee Offsets
|
$0.00
|
|||||||||||||||
Net Fee Due
|
$540.59
|
(1) |
Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, (the “Securities Act”), this Registration Statement shall also cover any additional shares of Ocuphira Pharma, Inc. (the “Registrant”) common stock that
become issuable under the Registrant’s 2020 Equity Incentive Plan (the “2020 Plan”) set forth herein by reason of any stock dividend, stock split, reclassification, recapitalization, spin-off or other similar transaction effected without
receipt of consideration that increases the number of outstanding shares of Registrant’s common stock, as applicable.
|
(2) |
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act. The offering price per share and aggregate offering price are based on the average of
the high and low prices of the Registrant’s common stock as reported on the Nasdaq Capital Market on January 5, 2024.
|
(3) |
Represents 1,198,875 additional shares of Common Stock available for issuance as a result of the annual evergreen increase on January 1, 2024 under the 2020 Plan.
|
1 Year Ocuphire Pharma Chart |
1 Month Ocuphire Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions